Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. J of Skin. 2024;8(1):s309. doi:10.25251/skin.8.supp.309